Investigational drug · Phase 3
HB0025
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for First-line pMMR Endometrial Cancer, Non Squamous Non-small Cell Lung Cancer, TNBC.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "HB0025"
First trial start
2024
Jan 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB0025", any sponsor or status.
Conditions studied
As listed on its trial records.
- First-line pMMR Endometrial Cancer
- Non Squamous Non-small Cell Lung Cancer
- TNBC
- Advanced NSCLC
- Advanced Endometrial Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HB0025" as an intervention, largest first.
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07383116 · 500 participants (planned) · Start Jan 15, 2026 · Primary completion Apr 10, 2028
Drug: Pemetrexed injection; Carboplatin Injection and 3 more · For: Non Squamous Non-small Cell Lung Cancer
Sites: Shanghai, China
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07360132 · 480 participants (planned) · Start Jan 15, 2026 · Primary completion Apr 10, 2028
Drug: Carboplatin Injection; Paclitaxel Injection · For: Squamous Non-small Cell Lung Cancer
Sites: Shanghai, China
- HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial CancerPivotal-lookingRecruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07902999 · 333 participants (planned) · Start Oct 20, 2026 · Primary completion Apr 23, 2029
Drug: HB0025 Injection; Paclitaxel injection and 1 more · For: First-line pMMR Endometrial Cancer
Sites: Guangzhou, China; Shenyang, China
Huabo Biopharm Co., Ltd.Industry
NCT06758557 · 282 participants (planned) · Start Jan 31, 2024 · Primary completion Oct 31, 2025
Drug: HB0025; Pemetrexed and 2 more · For: Advanced NSCLC; Advanced Endometrial Cancer
Sites: Baoding, China; Harbin, China; Luoyang, China · 14 sites in all
Huabo Biopharm Co., Ltd.Industry
NCT04678908 · 154 participants (planned) · Start Mar 10, 2021 · Primary completion Feb 2, 2024
Drug: HB0025 · For: Tumor, Subjects
Sites: San Antonio, Texas; Bengbu, China; Jinan, China · 6 sites in all
Huabo Biopharm Co., Ltd.Industry
NCT06222125 · 100 participants (planned) · Start Jan 30, 2023 · Primary completion Jan 30, 2025
Drug: HB0025 · For: Renal Cancer
Sites: Shanghai, China
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitation
Huabo Biopharm Co., Ltd.Industry
NCT07376629 · 60 participants (planned) · Start Aug 14, 2025 · Primary completion Jan 15, 2027
Drug: HB0025 20 mg/kg plus nab-paclitaxel; HB0025 10 mg/kg plus nab-paclitaxel · For: TNBC
Sites: Anyang, China; Changsha, China; Chengdu, China · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- HB0025, a Novel Anti-PD-L1/VEGF Trap Bispecific Antibody Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
D'Aiello A, Halmos B · JAMA Oncol 2026
- HB0025 With Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zhou F, Wang L, Bai J, et al. · JAMA Oncol 2026
- PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026.
Wang Z, Guo C, Yuan X, et al. · J Hematol Oncol 2026
- A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
Cui X, Jia H, Xin H, et al. · Front Immunol 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.